ACXEL (Aosu Tech), operating as acx INSTRUMENTS, ranks first in the growth enterprise category of Cyzone/36Kr’s 2025 China Enterprise Globalization New Forces 100 list. The selection cites the company’s global strategy, technological innovation, and influence in overseas markets as reasons for its recognition.
ACXEL (奥素科技) leads a project with Beijing Institute of Technology that receives an approximately RMB 20 million grant under the 2024 National Key R&D Program’s Frontier Biotechnology special. The project focuses on development and application research for an optoelectronic microfluidic platform. The award marks national recognition of ACXEL’s research and development in frontier biotechnology.
Acxel Boxin Tech raises nearly RMB 100 million in a Series A round to advance its digital microfluidics platform. Luxin Venture Capital leads the financing, with Qiming participating.
Acxel secures nearly RMB 100 million in Series A financing, with Qiming continuing its participation. The company plans to use the funding to accelerate commercialization of single-cell proteomics.
